Despite this, the advantage of the CAR-NK framework was observed in vivo in both CD3 and CD5 CAR constructs, as CD3-CAR in a CAR-NK framework significantly reduced the tumor burden and CD5-CAR in a CAR-NK framework completely eliminated the tumor. This evidence concerns the gene CD5 and neoplasm.